Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake

Mazumdar, Shahana; Tripathy, Koushik; Sarma, Barsha; Agarwal, Neetu

doi:10.1177/1120672118797286

Cited by 11 publications

(12 citation statements)

References 8 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In posterior scleritis, the angle closes and AC becomes shallow due to choroidal and supraciliary effusion with swelling and anterior rotation of the ciliary body which results in a forward shift of the iris lens diaphragm. The same mechanism is seen in ACG in conditions including excessive panretinal photocoagulation and drugs (oral topiramate [10], topical pilocarpine). The management includes cycloplegia with atropine and management of the cause (i.e.…”

Section: Discussionmentioning

confidence: 91%

Panscleritis masquerading as an attack of primary acute angle closure glaucoma

Bashir

Sridhar

Mazumdar

et al. 2019

GMS Ophthalmology Cases; 9:Doc31

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Panscleritis masquerading as an attack of primary acute angle closure glaucoma

Bashir

Sridhar

Mazumdar

et al. 2019

GMS Ophthalmology Cases; 9:Doc31

Self Cite

View full text Add to dashboard Cite

“…1 ]. [ 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 ]…”

Section: Resultsunclassified

Topiramate-induced acute angle closure: A systematic review of case reports and case series

Owaifeer

AlSultan

Badawi

2022

Indian J Ophthalmol

View full text Add to dashboard Cite

Topiramate-induced acute angle closure (TiAAC) is a potentially vision-threatening side effect of topiramate (TPM) use. The purpose of this article is to review demographic characteristics, clinical features, and management options of TiAAC. A systematic literature search of all reported cases and case series of TiAAC was conducted in the following search engines: PubMed, Web of Science, Google Scholar, Elsevier, and EBSCO. Seventy-three publications describing 77 cases were included. 58 (75.3%) patients were female, and the mean age was 34.88 ± 11.21 years (range, 7–57). The most commonly reported indication of TPM use was migraine headache (59.7%), and the mean duration from starting treatment until the onset of angle closure was 14.1 ± 31.5 days. All cases were managed by immediate cessation of TPM and topical therapy. In addition, systemic medications (carbonic anhydrase inhibitors, hyperosmotic agents, and steroids) were used in 51 patients (66.2%). A laser and/or surgical intervention was performed in 10 patients (13%). After commencement of treatment, the mean duration until the resolution of TiAAC was 3.9 ± 3.6 days (range, 1–18). The findings of our study present a summary of the current body of evidence provided by case reports and case series on TiAAC. In conclusion, the onset of angle closure following TPM use peaks at 2 weeks after initiating treatment, and in most cases, successful management can be achieved by discontinuing TPM and initiating appropriate medical therapy.

show abstract

“…[ 11 ] Topiramate, another antiepileptic agent, can also cause neurosensory retinal detachment. [ 12 ] Furthermore, pregabalin add-on therapy may result in downbeat nystagmus.13 These case reports are in parallel indicating a probable causal link between antiepileptic medications and occurrence of ocular disorders such as CSCR.…”

Section: Discussionmentioning

confidence: 99%

“…[ 11 ] Another case report suggests that topiramate, an antiepileptic agent, may be linked to acquired myopia followed by neurosensory retinal detachment at the posterior pole in left eye. [ 12 ] Pregabalin add-on therapy has been also reported as a probable cause for the occurrence of downbeat nystagmus. [ 13 ]…”

Section: Introductionmentioning

confidence: 99%

Pregabalin as a probable cause of central serous chorioretinopathy: Two case reports

Doğan¹,

Oktay²,

Özkurt³

et al. 2021

Turk J Phys Med Rehab

View full text Add to dashboard Cite

Pregabalin is commonly used for the treatment of neuropathic pain and is attributed to adverse effects of peripheral vasodilation and peripheral edema. Central serous chorioretinopathy (CSCR) is characterized by choroidal fluid leaks from choroidal vessels under the retina, causing focal retinal detachment with macular vision loss. Herein, we report two cases admitted to our clinic with vision loss while under pregabalin treatment. Upon eye examination, both patients were diagnosed with acute CSCR. Pregabalin treatment was discontinued upon the diagnosis of CSCR. We consider that the use of pregabalin in the presented two cases may be the causal effect of the CSCR diagnosis, as pathophysiology of CSCR is in parallel with the edema-related adverse effects of pregabalin.

show abstract

Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake

Abstract: A unique case of central serous chorioretinopathy following oral intake of topiramate is presented. This patient had also received laser peripheral iridotomy and topical steroids following the peripheral iridotomy.

Cited by 11 publications

References 8 publications

Panscleritis masquerading as an attack of primary acute angle closure glaucoma

Panscleritis masquerading as an attack of primary acute angle closure glaucoma

Topiramate-induced acute angle closure: A systematic review of case reports and case series

Pregabalin as a probable cause of central serous chorioretinopathy: Two case reports

Contact Info

Product

Resources

About